Supercharging Immune Cells: A New Hope for Long-Term HIV Control with CAR-T Therapy

A groundbreaking cancer therapy, known as CAR-T cell therapy, which involves genetically engineering a patient's own immune cells, is now showing remarkable promise in the long-term control of HIV. Early results from a pioneering clinical trial have revealed that two individuals living with HIV have achieved undetectable levels of the virus and have been able to discontinue their antiretroviral medications entirely for nearly two years and almost one year, respectively, after a single infusion of the modified cells. These initial findings, announced last week at the American Society of Gene and Cell Therapy annual meeting in Boston, mark a significant step in the ongoing quest for a functional cure for HIV. At its core, CAR-T cell therapy works by reprogramming a patient's T-cells in a laboratory to specifically recognize and attack HIV within the body. This small study primarily aimed to test the treatment's safety and feasibility. Steven Deeks, a professor of medicine and HIV expert at the University of California, San Francisco, who led the trial, remarked, “These are early days. If we can provide the proof-of-concept that this approach is both safe and effective, then there are lots of ways in which it can be optimized, to make it more affordable and scalable.” The technique itself is well-established, having been successfully used in tens of thousands of patients with difficult-to-treat cancers and, more recently, severe autoimmune diseases, by essentially supercharging the immune system. The search for a definitive cure for HIV has been ongoing since the virus's identification in the early 1980s. While antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, allowing near-normal life expectancy, it requires life-long medication and faces challenges in accessibility and awareness, particularly in low-income regions. The concept of a “functional cure,” where the virus is suppressed to undetectable levels without medication, has only been achieved in a handful of documented cases, typically through intensive stem cell transplants for cancer patients. However, as Boro Dropulić, executive director of Caring Cross and developer of the CAR-T therapy for HIV, notes, stem cell transplants are not scalable, involve significant risks, and require specific donors. Andrea Gramatica, vice president of research at amfAR, the Foundation for AIDS Research, highlighted the study's importance: “It gives the HIV field a real, clinical clue that teaching the immune system to control the virus without antiretroviral therapy is achievable.” In this innovative approach, Dropulić and his team engineered patients' T cells to recognize two different sites on the HIV virus, making it harder for the virus to evade detection. The goal is for these modified cells to act as permanent “sentries” in the body, immediately addressing any viral replication. The trial included nine participants, all initially on ART. A first group of three received only CAR-T cells without a conditioning drug, leading to expected viral rebound. The other six volunteers received CAR-T cells along with a conditioning drug. Notably, the two individuals who achieved long-term viral suppression had started antiretroviral treatment soon after their initial HIV diagnosis, suggesting that early intervention might play a role in the therapy's success. While these results are incredibly promising, it is crucial to temper expectations regarding immediate widespread availability. The procedure to obtain the necessary T cells involves filtering large volumes of a patient's blood through a machine, followed by several weeks of laboratory processing to create the CAR-T cells. This complex and costly process means that even if the technique proves effective in a larger patient cohort, it will likely be years before it becomes widely accessible and affordable. Nevertheless, this study represents a significant leap forward, offering a tangible pathway towards a more accessible and sustainable long-term control, and potentially a functional cure, for HIV.